Agilent Technologies Secures Exclusive License to Aktiv-Dry CAN-BD Spray-Drying Technology for Nucleic Acid API's
"Agilent has long recognized that nucleic acid drying methods present a significant barrier to economic production of nucleic acid therapeutics at commercial scale," said James Powell, general manager of Agilent's Nucleic Acid Solutions Division. "We have been actively evaluating alternative technologies, and we are now confident that Aktiv-Dry's CAN-BD technology will significantly lower cost-of-goods for our customers while providing a higher-quality nucleic acid API."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.